Neuraxis (NRXS) Capital Expenditures (2022 - 2025)

Neuraxis (NRXS) posted Capital Expenditures of $5862.0 for Q4 2025, down 19.57% sequentially from $7288.0 in Q2 2025.

Neuraxis (NRXS) Capital Expenditures (2022 - 2025) Analysis & Trends

Neuraxis has reported Capital Expenditures for 4 years, with the latest figure at $5862.0 in Q4 2025.

Quarterly Capital Expenditures changed N/A year-over-year to $5862.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $31150.0 (up 12.15% YoY) and the FY2025 annual result came in at $31150.0, up 12.15% from the prior year.
Capital Expenditures declined to $5862.0 in Q4 2025 per NRXS's latest filing, from $7288.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $18000.0 in Q1 2025 and troughed at -$10000.0 in Q4 2022.
A 4-year average of $7246.1 and a median of $7288.0 in 2025 frame the typical range for Capital Expenditures.
The sharpest annual moves came in 2023 and 2025: Capital Expenditures jumped 260.4% in 2023, then retreated 16.09% in 2025.
Over 4 years, Capital Expenditures stood at -$10000.0 in 2022, then surged by 260.4% to $16040.0 in 2023, then slumped by 72.77% to $4368.0 in 2024, then jumped by 34.2% to $5862.0 in 2025.
According to Business Quant data, Capital Expenditures over the past three periods registered $5862.0, $7288.0, and $18000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Neuraxis	74.54 Mn	66.21 Mn	-	-

Download Data